Charting the Future at Johnson & Johnson MedTech: An Interview with Ashley McEvoy

article image

At one of this year’s Stanford Biodesign Innovator’s Workbench programs, Ashley McEvoy, head of J&J’s MedTech business, talked about the current state of the company’s medical device businesses, the impact of the COVID pandemic, and what the future holds for J&J MedTech.

It goes to the very essence of Johnson & Johnson that while the company was one of those that benefited—if that’s an appropriate term—from a COVID pandemic that has rocked the world for the past two-plus years, as a result of its role in the development of a COVID vaccine, it’s medical device business, like every other medtech company, saw a dramatic downturn as the pandemic filled hospital beds and all but cancelled elective procedures at hospitals over-stressed by a pandemic that has seemed relentless.

It is, in fact, one of the strengths of Johnson & Johnson as one of the few remaining healthcare product companies with a major foothold in both pharmaceuticals and medical devices, that when one part of its business faces difficult times, other parts can, in a way, compensate. Thus, over the past two years, while the medical device business has felt the brunt of the pandemic in the form of fewer in-hospital procedures, the pharma side of the business has rallied from a mid-200s slump and been a leader in vaccine development.

That’s some solace for Ashley McEvoy, who, asEVP and Worldwide Chairman of Johnson & Johnson MedTech,has had the responsibility for managing the MedTech business through the pandemic, overseeing some of the industry’s most powerful brands, including Ethicon and DePuy.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: